Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252111512 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Rafael Jiménez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Faculty of Biosciences, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia, Innovación y Universidades, Agència de Gestió d'Ajuts Universitaris i de Recerca, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Glioblastoma (GB) is an aggressive malignant central nervous system tumor that is currently incurable. One of the main pitfalls of GB treatment is resistance to the chemotherapeutic standard of care, temozolomide (TMZ). The role of aldehyde dehydrogenases (ALDHs) in the glioma stem cell (GSC) subpopulation has been related to chemoresistance. ALDHs take part in processes such as cell proliferation, differentiation, invasiveness or metastasis and have been studied as pharmacological targets in cancer treatment. In the present work, three novel α,β-acetylenic amino thiolester compounds, with demonstrated efficacy as ALDH inhibitors, were tested in vitro on a panel of six human GB cell lines and one murine GB cell line. Firstly, the expression of the ALDH1A isoforms was assessed, and then inhibitors were tested for their cytotoxicity and their ability to inhibit cellular ALDH activity. Drug combination assays with TMZ were performed, as well as an assessment of the cell death mechanism and generation of ROS. A knockout of several ALDH genes was carried out in one of the human GB cell lines, allowing us to discuss their role in cell proliferation, migration capacity and resistance to treatment. Our results strongly suggest that ALDH inhibitors could be an interesting approach in the treatment of GB, with EC50 values in the order of micromolar, decreasing ALDH activity in GB cell lines to 40–50%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Faculty of Biosciences, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain.
- Institute for Biotechnology and Biomedicine, Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain.
- Unit of Research in Cellular and Molecular Biology, Advanced BioDesign, Saint-Priest, 69800 Lyon, France.
- Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, E-08193 Bellaterra, Spain.
- Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, E-08913 Bellaterra, Spain.
ORCID-Profile: Xavier Parés, Mileidys Pérez-Alea, Ana Paula Candiota, Jaume Farrés, Julia Lorenzo
Förderung
- Ministerio de Ciencia, Innovación y Universidades
- Agència de Gestió d'Ajuts Universitaris i de Recerca
- Instituto de Salud Carlos III
- Spanish Ministerio de Ciencia e Innovación
- Agència de Gestió d’Ajuts Universitaris i de Recerca
Zitieren
APA
Jiménez, R., Constantinescu, A., Yazir, M., Alfonso-Triguero, P., Pequerul, R., Parés, X., Pérez-Alea, M., Candiota, A. P., Farrés, J., & Lorenzo, J. (2024). Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252111512
Vancouver
Jiménez R, Constantinescu A, Yazir M, Alfonso-Triguero P, Pequerul R, Parés X, et al. Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252111512
BibTeX
@article{Jimnez2024,
author = {Jiménez, Rafael and Constantinescu, Andrada and Yazir, Muhube and Alfonso-Triguero, Paula and Pequerul, Raquel and Parés, Xavier and Pérez-Alea, Mileidys and Candiota, Ana Paula and Farrés, Jaume and Lorenzo, Julia},
title = {Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252111512}
}
EUVIMED